A joint venture (JV) between 3SBio and CPE Funds has entered an asset purchase agreement to purchase Canadian biologics manufacturer Therapure Biopharma’s contract development and manufacturing (CDMO) business, Therapure Biomanufacturing, for $290m.

Upon completion of the deal, the business will continue to run under the Therapure brand and will be led by the company’s chief executive officer Nick Green and the current senior management team at its manufacturing facilities located in Mississauga, Ontario, US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, Catalyst Capital Group will retain ownership of and also support future investments in Therapure’s plasma protein and therapeutic products business under a separate entity named ProductsCo.

In addition, the JV provides the CDMO business access to greater mammalian cell and downstream purification manufacturing capabilities.

It also provides strategic support for the expansion of Therapure’s CDMO business and facilities, offering employees and stakeholders with enhanced opportunities across Canada.

"This transaction is exciting for the future of Therapure and for the Canadian biopharma industry."

Operationally, the CDMO will continue to manufacture clinical material with the team’s expertise in plasma proteins production in the existing facilities, as well as build a new commercial facility on behalf of ProductsCo for the development of its plasma proteins commercial portfolio.

The acquisition will enable ProductsCo to focus on the clinical development and commercialisation of its plasma proteins in high growth markets, initially in the US and Canada.

Green said: “This transaction is exciting for the future of Therapure and for the Canadian biopharma industry.

“It will be a powerful enabler for further growth and expansion of both 3SBio and Therapure in high growth areas of the market through our combined capabilities. This will put us in a stronger position to lead, innovate and grow, and further support our current and future clients.”

The transaction is expected to be concluded by the end of this year.